CpG ODN enhances the UPR and sensitivity to bortezomib. (A) RT-PCR for XBP1 spliced and unspliced (398- and 424-base pair fragments, respectively) forms in CpG ODN–treated Jeko-1 cells with and without bortezomib. (B) Relative clonogenic recovery of cells treated with CO or CpG ODN with or without bortezomib (*P < .05, **P < .01; n = 4). (C) Relative clonogenic recovery of Jeko-1 cells treated with CO or CpG ODN with or without bortezomib (10nM), daunorubicin (1nM), dexamethasone (1nM), or etoposide (0.1nM) or vehicle control (*P < .01; n = 3). (D) Quantitative RT-PCR for CHOP in Jeko-1 cells after treatment with phosphate-buffered saline vehicle, CO, or CpG ODN and bortezomib (**P < .02; n = 3).